Abstract
Bromodomains (BRDs) are important protein domains in the reading process of epigenetic marks. Recent studies have demonstrated that human BET protein BRD4 which contains bromodomains plays a critical role in cell proliferation, cancer growth and virus-host pathogenesis. In this work, a chemical-core substitution strategy was employed to identify BRD4 bromodomain inhibitors that had new and different chemical cores featuring common chemical portions with the parent fragments. After the combination of compounds BI2536 and GSK726, two hit compounds 6h and 6i represented potent lead compounds to deserve further optimization. Then, ten analogous compounds were synthesized and evaluated by in-vitro biological test. Among them, compound 6d exhibited the greatest inhibition against BRD4 bromodomains with IC50 value of 180 nM.
Keywords: Epigenetic, BRD4, chemical-core substitution, quinoxalone derivatives, biology, optimization
Letters in Drug Design & Discovery
Title:Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors
Volume: 14 Issue: 1
Author(s): Bin Xu, Lei-Lei Zhao, Yi-Fei Yang, Jian Zhang, Ling-Yun Yang, Bing Zhang, Li Han, Hui-Bin Zhang and Jin-Pei Zhou
Affiliation:
Keywords: Epigenetic, BRD4, chemical-core substitution, quinoxalone derivatives, biology, optimization
Abstract: Bromodomains (BRDs) are important protein domains in the reading process of epigenetic marks. Recent studies have demonstrated that human BET protein BRD4 which contains bromodomains plays a critical role in cell proliferation, cancer growth and virus-host pathogenesis. In this work, a chemical-core substitution strategy was employed to identify BRD4 bromodomain inhibitors that had new and different chemical cores featuring common chemical portions with the parent fragments. After the combination of compounds BI2536 and GSK726, two hit compounds 6h and 6i represented potent lead compounds to deserve further optimization. Then, ten analogous compounds were synthesized and evaluated by in-vitro biological test. Among them, compound 6d exhibited the greatest inhibition against BRD4 bromodomains with IC50 value of 180 nM.
Export Options
About this article
Cite this article as:
Xu Bin, Zhao Lei-Lei, Yang Yi-Fei, Zhang Jian, Yang Ling-Yun, Zhang Bing, Han Li, Zhang Hui-Bin and Zhou Jin-Pei, Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors, Letters in Drug Design & Discovery 2017; 14 (1) . https://dx.doi.org/10.2174/1570180813666160715160857
DOI https://dx.doi.org/10.2174/1570180813666160715160857 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part I: Xanthones, Quinones, Steroids, Coumarins, Phenolics and other Classes of Compounds
Anti-Cancer Agents in Medicinal Chemistry Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Anti-Cancer Drug Discovery The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Investigation of the Pharmacokinetics of the ABCG2 Transporter Inhibitor Ko134 in Mice by a Newly Developed and Validated HPLC Method
Current Pharmaceutical Analysis